Loading...
Loading...
PRTG| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 15.0K |
| Gross Profit | -15.0K |
| Operating Expense | 5,945.0K |
| Operating I/L | -5,930.0K |
| Other Income/Expense | -142.0K |
| Interest Income | 53.0K |
| Pretax | -6,072.0K |
| Income Tax Expense | -907.0K |
| Net Income/Loss | -5,158.0K |
Portage Biotech Inc. and its subsidiaries specialize in researching and developing pharmaceutical and biotechnology products. Their product portfolio includes a range of innovative treatments such as IMM60, IMM65, INT230-6, STING, CellPorter, PPL-003, and SBI-101, targeting various medical conditions including cancer, ophthalmic disorders, and acute vital organ injuries. The company also focuses on nanolipogel technology for immune-oncology, antibodies for malignancies, and antibodies related to inflammatory tumor and immune cell microenvironments. Additionally, they are developing the FOXO4-P53 modulator and C-RAF inhibitor. These products form the core of their revenue generation and business operations.
